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Running title: Gene polymorphisms and therapy in rheumatoid arthritis  
 
Abbreviations: 
ABCB1: ATP-binding cassette, sub-family B, member 1 
ACR: American College of Rheumatology 
5-ASA: 5-aminosalicylic acid 
ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclo-
hydrolase 
BAFF: B-cell activating factor 
CARD8: caspase recruitment domain-containing protein 8 
CDAI: clinical disease activity index 
CHUK: conserved helix-loop-helix ubiquitous kinase 
CYP1A2: cytochrome P450 1A2 
CYP2C19: cytochrome P450 2C19 
CYP3A4: cytochrome P450 3A4 
DAS28: 28 joint count disease activity score 
DHODH: dihydroorotate dehydrogenase 
DMARD: disease-modifying antirheumatic drugs   
ESR1: estrogen receptor 1 
EULAR: European League Against Rheumatism 
FCG3A: Fc region receptor III-A 
GWAS: genome-wide association study 
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HAQ: health assessment questionnaire 
HLA: human leukocyte antigen 
HLA-DRB1: major histocompatibility complex, class II, DR beta 1 
IL: interleukin 
JAK: Janus kinase pathway 
MTHFR: methylene tetrahydrofolate reductase 
NAT: N-acetyltransferase 
NF-kB: nuclear factor-kappa B 
NLRP3: NOD-like receptor family, pyrin domain 3 
PADI4: peptidyl arginine deiminase, type IV 
PDE3A: phosphodiesterase 3A 
PTPN22: protein tyrosine phosphatase, non-receptor type 22 
PTPRC: protein tyrosine phosphatase, receptor type C 
RFC-1: reduced folate carrier 1 
SLC19A1: solute carrier family 19 (folate transporter), member 1 
SNP: single nucleotide polymorphism 
TGFb: transforming growth factor β 
TNF: tumor necrosis factor 
TNFi: TNF inhibitors  
TYMS: thymidylate synthetase 
TSER: thymidylate synthase enhancer region 
UTR: in molecular genetics, untranslated region
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Keywords: biologic therapy, disease-modifying antirheumatic drugs (DMARDs), 
pharmacogenetics, pharmacogenomics, rheumatoid arthritis 
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1. Introduction  
Rheumatoid Arthritis (RA) is a chronic inflammatory and autoimmune disease 
characterized by the progressive destruction of the joints. RA is associated with 
increased morbidity and mortality. The disease is more frequent in women (3:1) and 
shows prevalence around of 0.5-1% in developed countries [1]. RA is a complex, 
polygenic and heterogeneous disease characterized by intricate interactions between 
genetic and environmental factors. The main genes related to susceptibility and severity 
of the disease are located in the major histocompatibility complex- HLA- region. 
Specifically, the HLA-DRB1 alleles, encoding the so-called shared epitope (SE), can 
explain around 40% of the genetic burden of disease [2]. Other important genes related 
to susceptibility and/or severity of the disease are PTPN22, PADI4 and some loci 
related with the TNFα pathway [3,4]. 
The course and prognosis of RA has changed considerably since the advent of biologic 
treatments. An early diagnosis and treatment along with tight control of the disease have 
improved the outcome of the disease. The mainstay of treatment for RA is currently 
based on two different therapeutic groups: conventional or synthetic disease-modifying 
antirheumatic drugs (DMARDs) and biological DMARDs, including TNF inhibitors 
(TNFi), monoclonal antibody directed against CD20 receptor of B cells (rituximab), IL-
6 receptor antagonist (tocilizumab) and a specific neutralizer of the union between 
CD80/CD86 at antigen presenting cell and CD28 at T lymphocyte surface (abatacept). 
In last years, a new generation of “targeted” DMARDs, i. e. JAK inhibitors, are 
available in several countries and recommended by some clinical guidelines for the 
management of RA. Nevertheless, these agents have not yet been well studied in terms 
of predictors of response beyond the usual disease characteristics. 
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2. Pharmacogenomics steps toward personalized medicine 
Regrettably, the response to the therapy in RA is not uniform; rather, there is wide 
interindividual variability in the response. On the other hand, the possibility of side 
effect due to the therapy is not negligible. Furthermore, the high costs of these new 
therapies place a heavy burden on governments. Because of that, the search for tools 
that can help select the patients who are more appropriate for each specific therapeutic 
target is of major importance. In this regard, an objective to be reached in the near 
future is the personalized medicine by using biomarkers that can predict the response to 
treatment and avoid the possible occurrence of adverse effects (AEs) individually. This 
is especially true since at present 40-60% of patients with RA fail to achieve a 
satisfactory response to DMARDs, and around 15-30% can develop adverse drug events 
[5]. 
Pharmacogenetics and pharmacogenomics hold a special interest in the search 
for possible accurate genetic markers that can predict the target and the response to a 
specific therapeutic target. Pharmacogenetics focuses on the study of genetic variations 
that determine the differential response to drugs as well as the prediction about the 
efficacy and occurrence of AEs with a specific drug in a particular an individual patient. 
In this issue of the Journal, Tarnowski et al performed an exhaustive review of the 
literature on the most important genetic variants involved in the metabolism of synthetic 
and biological DMARDs [6]. 
Despite the fact that genetic factor are of major importance in the response to the 
therapy, it is important to keep in mind that “non-genetic” factors, such as demographic 
and environmental factor as well as clinical or serologic markers can influence or 
predict the efficacy or toxicity of a drug in patients with RA, sometimes even better 
than the genetic biomarkers [7]. This is the case for the age, sex or smoking. For 
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 6 
example, younger patients with RA tend to respond better to therapies and active 
smokers worse, possibly because they have higher levels of pro-inflammatory 
cytokines. Also, some parameters related to the disease itself, such as duration or 
activity and health assessment questionnaire (HAQ) at baseline may influence the 
response to therapy. In general, the higher basal activity or worse HAQ are the poorer is 
the response [7]. 
 
3. Pharmacogenetics on conventional (synthetic) DMARDs 
In their manuscript, Tarnowski et al review the main gene polymorphisms related to the 
efficacy or toxicity of methotrexate (MTX), leflunomide and sulfasalazine [6]. With 
respect to MTX, many genes are involved in its transportation into cells and out of 
them, its polyglutamation and the inhibition of the synthesis of purines, pyrimidines or 
DNA repair. Nevertheless, few are the genes in which polymorphisms show interest 
from a point of view of efficacy and toxicity [8,9]. Firstly, it has been shown that the 
80AA genotype of RFC-1 (also called SLC19A1) gene that carries MTX into the cell 
interior has been associated with a better response. Also, carriers of the 3435(C>T) T 
allele located in the exon 26 of the ABCB1 gene, which returns MTX outside of the 
cells, appear to have better response to MTX.  
In contrast, RA patients carrying a triple repeat sequence in the homozygous form at the 
5´-UTR end of the TYMS (thymidylate synthetase) gene (TSER*3/*3) need higher doses 
of drug to obtain the same effects, whereas six-base pair deletion in the 3´-UTR region 
individuals have a good response to conventional doses of MTX [10]. In the case of 
polymorphisms 677C/T and 1298A/C of the MTHFR gene, results related to efficacy or 
toxicity are not conclusive. Finally, the C>G polymorphism at the 347 position in the 
ATIC gene is associated with increased efficacy and toxicity [10].  
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Regarding leflunomide, the most relevant enzymatic ways studied are the DHODH, a 
key enzyme of de novo pyrimidine synthesis, and the cytochrome pathway. As 
Tarnowski et al pointed in their review [6], it seems that individuals with RA carrying 
the 19AA genotype in the coding region of DHODH have lower rate of remission 
compared with those C allele carriers [10,11].   
Results regarding several SNPs in the cytochrome pathway, especially in the CYP1A2, 
CYP2C19 and CYP3A4 genes, are inconclusive and appear to be more related to drug 
toxicity. An interesting aspect related to the efficacy of leflunomide is the possible 
association between some polymorphisms at the estrogen receptor 1 (ESR1) and a better 
response to this drug in women [11]. 
Sulfasalazine (SASP) is another drug commonly used in low-grade RA. SASP is 
converted into 5-ASA and sulfapyridine, and later it is metabolized in the liver through 
acetylation by N-acetyltransferases (NAT1, NAT2). Slow acetylators due to 
polymorphisms in these genes, especially in NAT2, are at increased risk of developing 
toxicity. The prevalence of slow acetylators varies greatly between races; 20% in 
Asiatic individuals and 60% in Africans or Caucasian. Yet, common doses of SASP 
seem to be more effective in patients with RA who are slow acetylators [10]. 
Overall, the study of SNPs in genes involved in the metabolism of conventional 
(synthetic) DMARDs seems to be more useful in detecting patients susceptible to 
develop toxicity, since these drugs induce a high rate of AEs. Table 1 summarizes the 
candidate genes and SNPs implicated in the efficacy and/or toxicity of conventional 
DMARDs. 
Finally, in last years, a new generation of promising “targeted” DMARDs (JAK 
inhibitors) has been developed. Nevertheless, these agents have not yet been extensively 
studied in terms of pharmacogenetics and prediction of response in patients with RA. 
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4. Pharmacogenetics of biologic DMARDs 
Unlike conventional DMARDS, biologic DMARDS are high-cost drugs and, due to 
this, studies on these new agents are focused on the search of good responders. 
Unfortunately, although this is an exciting issue, there are few polymorphisms that so 
far have shown a significant participation in the prediction of the efficacy or safety of 
these drugs in clinical practice. 
4.1 TNF inhibitors (TNFi)  
Regarding TNFα antagonists, most studies were conducted on small numbers of patients 
with controversial results. The most interesting data seem to be related to some SNPs 
located at -238, -308 and -857 positions in TNF promoter region with questionable 
results. In this regard, although some studies found that -308GG genotype was 
associated with a good response to TNFi, especially to etanercept; two recent meta-
analyses concluded that the -308G/A polymorphism of TNF is not a good predictor of 
clinical response to TNFi [12,13]. By contrast, a sensitivity analysis revealed a possible 
association between response to infliximab and the TNF -238A/G polymorphism [12]. 
Other studies have demonstrated association between clinical response and some 
polymorphisms in TNFα receptor genes.  
A meta-analysis involving more than 2 million common variants in 2706 RA patients 
disclosed a positive association between CD84 expression and response to etanercept. 
Other genes that have been associated with satisfactory and consistent results in terms 
of response to various anti-TNF agents are NLRP3/CARD8 (encoding NLRP3-
inflammasome), PTPRC, PDE3A, NF-kB and CHUK [14,15]. In contrast, no association 
has been detected with other important genes involved in RA pathogenesis such as the 
IL-6 receptor gene, HLA-DRB1 shared epitope, PTPN22 or TGFb [7]. A summary of 
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 9 
the main genes and polymorphisms implicated in the efficacy and safety of biologic 
DMARDs is shown in Table 2. 
4.2 Other biologic DMARDs 
Experience with the use of other biologics is more limited. In the case of tocilizumab, it 
appears that some variants in the gene of IL-6 receptor, located in exon 9 and introns 1 
and 9, could be associated with a poorer clinical response when the AAC haplotype is 
expressed. 
Regarding rituximab, the available information is quite poor. Nevertheless, some 
polymorphisms located in the IL-6 (174G/C), TGFB1, FCG3A and promoter region of 
BAFF genes suggest promising results. Table 2 shows a more detailed information on 
the main genes related to response to biologic DMARDs. 
 
5. Conclusions 
Pharmacogenetics is a discipline that can provide important solutions to the problems 
related to the management of chronic and complex diseases such as RA. This is 
especially true for drugs that have a high rate of AEs (conventional DMARDs) or a high 
cost (biological DMARDs), where besides safety and efficacy criteria, cost-
effectiveness criteria should also be kept in mind. Pharmacogenetics and related 
disciplines can yield answer to many of these issues, although there are still many 
questions to be elucidated. 
 
6. Expert Opinion 
At present, we are still far from being able to apply the concepts known on the 
pharmacogenetics of DMARDs into clinical practice. This can be due to several 
reasons. First, RA is a polygenic, heterogeneous and complex disease, in which many of 
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the pathogenic mechanisms are not well known. Furthermore, much of the research 
conducted have been focused on candidate genes related to susceptibility or severity of 
the disease that are not necessarily the same as those involved in the response to 
treatment. Likewise, in many cases results of different studies show contradictory or 
inconclusive conclusions. 
Low statistical power due to small sample size is another important factor that reduces 
the potential relevance of most studies. Selection bias, heterogeneity of the populations 
studied and lack of replication are also important limitations. 
Other factors such as race and sex, duration of the disease, smoking as well as other 
environmental and epigenetic factors account for the disparity of the results obtained in 
different pharmacogenetic studies. The presence or absence of antibodies to citrullinated 
peptide antigens, which in many studies is not especified, may greatly influence in the 
results. More importantly, there is no uniformity in the criteria used for the evaluation 
of the responses or remission between studies (i.e. DAS28, CDAI, EULAR or ACR 
responses). 
Taken together, we conclude that the use of pharmacogenetics in clinical practice in 
patients with RA is currently limited. Results derived from genome-wide association 
studies (GWAS) conducted in homogeneous and well characterized populations will 
allow us to obtain more reliable information. Also, the introduction of more powerful 
and complementary techniques based on pharmacogenomics, proteomics and 
transcriptomics will provide useful information to design individual therapeutic 
management. This is probably the only way towards personalized health care, focused 
on the search for greater efficiency and safety, with fewer side effects and a more cost 
effective approach for each patient. 
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Currently, with the available data, an approach for the treatment of a patient with RA is 
based on clinical aspects and tight control of the disease along with cost-effectiveness 
data, the experience of the physician and the available scientific evidence. In most cases 
the use of information related to gene polymorphisms associated with disease 
susceptibility and severity is not available. Nevertheless, we hope that in the near future 
the use of composite indexes mixing of genetic markers and clinical tools may improve 
the management of patients with RA. 
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Table 1. Pharmacogenetics of conventional (synthetic) DMARDs§. 
 
Abbreviations: ABCB1: ATP-binding cassette, sub-family B, member 1; ATIC: 5 
aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclo-hydrolase;  bp: 
base pair; CYP1A2: cytochrome P450 1A2; DHODH: dihydroorotate dehydrogenase; 
DMARDs: disease-modifying antirheumatic drugs; ESR1: estrogen receptor 1; MDR1: 
multidrug resistance 1; MTHFR: methylene tetrahydrofolate reductase; RFC-1: reduced folate 
carrier 1; SLC19A1: solute carrier family 19 (folate transporter), member 1; TYMS: 
thymidylate synthetase; SHMT1: serine hydroxymethyltransferase; TPMT: thiopurine 
methyltransferase; UTR: untranslated region. §Table modified from reference 10. 
Drug Gene Genetic variants Clinical effects 
 
Methotrexate RFC-1 (SLC19A1) 80G>A (AA genotype) Increased efficacy 
ABCB1 (MDR1) 3435C>T (T allele) Increased or 
unaffected efficacy 
 
MTHFR 677C>T Controversial results 
MTHFR 1298A>C Controversial results 
TYMS 5´-UTR repeat element Decreased efficacy; 
probably increased 
toxicity 
TYMS 3´-UTR, 6 bp deletion Increased efficacy 
ATIC 347C>G (GG genotype) Increased  toxicity    
and probably efficacy 
SHMT1 1420C>T Increased toxicity 
 
Leflunomide DHODH 19C>A (AA genotype) Decreased efficacy 
CYP1A2 CYP1A2*1F  
(CC genotype) 
Increased toxicity; 
efficacy ? 
 
ESR1 SNF Increased efficacy in 
women 
 
Sulfasalazine NAT2 NAT2*4 Increased toxicity in 
slow acetylators 
 
Azathioprine TPMT TPMT*2, *3ª, *3C Increased toxicity 
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Table 2. Pharmacogenetics of biological DMARDs§. 
 
Abbreviations: Anti-TNF agents: TNF neutralizing agents/TNF inhibitors; BAFF: B-cell 
activating factor; CARD8: caspase recruitment domain-containing protein 8; CD84: cluster 
differentiation number 84; DMARDs: disease-modifying antirheumatic drugs; ETN: etanercept; 
FCG3A: Fc gamma region type IIIA; FCGR2A: Fc region receptor II-A; NLRP3: NOD-like 
receptor family, pyrin domain 3; PTPRC: protein tyrosine phosphatase, receptor type C; SNP: 
single nucleotide polymorphism; TGFb: transforming growth factor β; TNF: tumor necrosis 
factor; TNFRSF1A (or 1B): tumor necrosis factor receptor superfamily, member 1. §Table 
modified from reference 10. 
 
Drug family Gene Genetic variants Clinical effects 
 
Anti-TNF agents TNF -238A>G (AA genotype) Increased efficacy 
TNF -308G>A (GG genotype) Increased efficacy, 
especially to ETN  
TNF -857C>T Controversial results 
 
TNFRSF1A Several SNPs Inconclusive results 
 
TNFRSF1B 196T>G Decreased efficacy or 
no effect  
CD84 SNPs Positive response to 
ETN 
FCGR2A H131R (RR genotype) Increased efficacy? 
FCGR3A 158V>F (FF genotype) Increased efficacy? 
 
NLRP3/CARD8 SNPs Increased efficacy 
 
PTPRC rs10919563 Increased efficacy 
 
Rituximab IL-6 -174G>C (CC genotype) Predictor of no 
response 
FCG3A 158V>F (V allele carriers) Discordant results, 
influenced by sex? 
 
TGFβ1 SNPs Small positive effect 
 
BAFF -871C>T (C allele carriers) Increased efficacy 
 
Tocilizumab IL-6 receptor AAC haplotype Decreased efficacy 
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